Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company whose core business is developing novel cancer therapies. The company’s drug development pipeline, as detailed in its public SEC filings, relies on animal testing as a standard and required component of its preclinical research. The company states that the “completion of extensive preclinical laboratory tests and animal studies” is part of its development process for product candidates like revumenib (Revuforj) and axatilimab (Niktimvo). This testing is conducted to satisfy regulatory requirements for safety and efficacy prior to human clinical trials.

As a pharmaceutical company with no marketed products, Syndax’s entire value proposition is built on advancing drug candidates through the regulatory pathway, which mandates animal data. The company’s research and development activities are therefore intrinsically linked to the commissioning and funding of animal testing.